Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase

 
 

  Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns  

 

Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022 .

 

   Key Highlights   

 
  • FY22 revenue increased 5% reported and organic
  •  
  • FY22 GAAP diluted EPS increased 40%; non-GAAP diluted EPS increased 26%
  •  
  • FY22 cash flow from operations of $7.3 billion increased 18%; FY22 free cash flow of $6.0 billion increased 22%
  •  
  • Quarterly dividend increased to $0.68 , annual $2.72 from prior $2.52 ; 45th consecutive year of dividend increases
  •  
  • Q4 revenue of $8.1 billion decreased 1% reported and increased 1% organic
  •  
  • Q4 GAAP diluted EPS of $1.10 increased 10%; non-GAAP diluted EPS of $1.52 increased 2%
  •  
  • Company issues FY23 guidance
  •  

Fiscal year 2022 revenue of $31.686 billion increased 5% as reported and organic, which excludes the $75 million negative impact of foreign currency translation. Unless otherwise stated, all revenue growth rates in this press release are stated on an organic basis, which excludes the impact of foreign currency translation. Fiscal year 2022 GAAP net income and diluted EPS were $5.039 billion and $3.73 , respectively, both increases of 40%. Starting with the quarter ended April 29, 2022 , the company will no longer adjust non-GAAP financial measures for certain license payments for, or acquisitions of, technology not approved by regulators. Historical non-GAAP financial measures detailed in the financial schedules included at the end of this release have been recast for comparability, resulting in a decrease in non-GAAP net income and diluted EPS of $78 million and $0.06 , respectively, for the fiscal year ended April 29, 2022 . After making this adjustment, fiscal year 2022 non-GAAP net income and diluted EPS were $7.505 billion and $5.55 , respectively, both increases of 26%.

 

Fiscal year 2022 cash flow from operations of $7.346 billion increased 18%. Fiscal year 2022 free cash flow of $5.978 billion increased 22%, representing free cash flow conversion from non-GAAP net earnings of 80 percent.

 

The company reported fourth quarter worldwide revenue of $8.089 billion , a decrease of 1% as reported and an increase of 1% on an organic basis, which excludes the $215 million negative impact of foreign currency translation. The company's fourth quarter revenue results were affected by temporary issues related to global supply chain, particularly in Surgical Innovations, and China , due to recent COVID-19 lockdowns.

 

Fourth quarter GAAP net income and diluted earnings per share (EPS) were $1.485 billion and $1.10 , respectively, increases of 9% and 10%, respectively. As detailed in the financial schedules included at the end of this release, fourth quarter non-GAAP net income of $2.038 billion was flat year-over-year, and fourth quarter non-GAAP diluted EPS of $1.52 increased 2%.

 

Fourth quarter U.S. revenue of $4.097 billion represented 51% of company revenue and decreased 2%. Non-U.S. developed market revenue of $2.609 billion represented 32% of company revenue and decreased 2% as reported and increased 4% organic. Emerging Markets revenue of $1.383 billion represented 17% of company revenue and increased 4% as reported and 7% organic. China revenue, which represented 43% of Emerging Markets revenue, declined 10% as a result of COVID-19 lockdowns.

 

"Global supply chain and COVID-19 controls in China created acute impacts to our results in the fourth quarter. We understand the root causes, we're addressing them, and we expect them to resolve over the near-term," said Geoff Martha , Medtronic chairman and chief executive officer. "We remain keenly focused on delivering innovation-driven growth with a robust pipeline of technologies in fast-growing markets, and we're committed to creating strong shareholder value through strategic capital allocation and active portfolio management."

 

   Cardiovascular Portfolio
 
The Cardiovascular Portfolio includes the Cardiac Rhythm & Heart Failure (CRHF), Structural Heart & Aortic (SHA), and Coronary & Peripheral Vascular (CPV) divisions. Fiscal year 2022 Cardiovascular revenue of $11.423 billion increased 6% as reported and 6% organic. Fourth quarter Cardiovascular revenue of $2.961 billion increased 2% as reported and 5% organic, driven by high-single digit organic growth in SHA and mid-single digit organic growth in CRM and CPV.

 
  •   Cardiac Rhythm & Heart Failure fourth quarter revenue of $1.552 billion increased 1% reported and 4% organic. Adjusting for the discontinuation of HVAD™ System sales, CRHF revenue increased 6% organic. Cardiac Rhythm Management revenue increased in the mid-single digits, with low-single digit growth in Defibrillation Solutions and high-single digit growth in Cardiac Pacing Therapies, including low-twenties growth in leadless pacemakers on the continued global adoption of Micra™ transcatheter pacing systems. Procedure Innovations revenue increased in the mid-twenties on strong sales of TYRX™ absorbable antibacterial envelopes. Cardiovascular Diagnostics revenue increased in the mid-single digits, and Cardiac Ablation Solutions revenue increased in the mid-single digits, driven by the adoption of LINQ II™ insertable cardiac monitors and Arctic Front Advance™ cryoballoon catheters and consoles, respectively.
  •  
  •   Structural Heart & Aortic fourth quarter revenue of $778 million increased 5% as reported and 8% organic. Structural Heart grew in the mid-teens, driven by mid-teens growth in transcatheter aortic valves (TAVR). Aortic declined in the mid-single digits due to product availability issues from supply chain and quality challenges. Cardiac Surgery increased in the high-single digits, driven by strength in the perfusion franchise.
  •  
  •   Coronary & Peripheral Vascular fourth quarter revenue of $631 million increased 1% as reported and 4% organic. Coronary & Renal Denervation (CRDN) increased in the low-single digits, with high-teens growth in Guide Catheters offsetting low-single digit declines in drug-eluting stents. Peripheral Vascular Health increased in the mid-single digits, driven by low-twenties endovenous growth on strong sales of the VenaSeal™ closure system and the Abre™ deep venous stent.
  •  

   Medical Surgical Portfolio
 
The Medical Surgical Portfolio includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions. Medical Surgical fiscal year 2022 revenue of $9.141 billion increased 5% as reported and organic. Excluding the impact of ventilator sales given the increased COVID-19 related demand in the prior year, Medical Surgical fiscal year 2022 revenue increased 9% organic. Medical Surgical fourth quarter revenue of $2.231 billion decreased 5% as reported and 1% organic, with flat year-over-year organic results in SI offset by mid-single digit organic declines in RGR. Excluding the impact of ventilator sales, Medical Surgical fourth quarter revenue was flat year-over-year organic.

 
  •   Surgical Innovations fourth quarter revenue of $1.491 billion decreased 3% as reported and was flat year-over-year organic due to supply constraints of certain raw materials. In addition, the division was affected by recent COVID-19 lockdowns in China , resulting in a mid-teens decline in SI revenue in China . These challenges resulted in Advanced Surgical Instruments declining in the low-single digits globally, including low-single digit declines in Advanced Stapling and mid-single digit declines in Advanced Energy. This was partially offset by high-teens growth in Hernia & Wound Management.
  •  
  •   Respiratory, Gastrointestinal & Renal fourth quarter revenue of $740 million decreased 7% as reported and 4% organic. Excluding the impact of ventilator sales, RGR revenue was flat year-over-year organic. Respiratory Interventions decreased in the mid-teens, with sales of ventilators declining in the mid-thirties as demand returned to pre-pandemic levels. Patient Monitoring increased in the mid-single digits, with mid-single digit growth in both Nellcor™ pulse oximetry products and Perioperative Complications products, offset by low-double digit declines in Respiratory Compromise solutions. Gastrointestinal revenue decreased in the mid-single digits given pressure on procedure volumes from COVID-19. Renal Care Solutions increased in the low-single digits, including high-single digit growth in acute therapies.
  •  

   Neuroscience Portfolio
 
The Neuroscience Portfolio includes the Cranial & Spinal Technologies (CST), Specialty Therapies, and Neuromodulation divisions. Neuroscience fiscal year 2022 revenue of $8.784 billion increased 7% as reported and organic. Neuroscience fourth quarter revenue of $2.299 billion was flat year-over-year as reported and increased 2% organic, with mid-single digit organic growth in Specialty Therapies and low-single digit organic growth in Neuromodulation partially offset by low-single digit organic declines in CST.

 
  •   Cranial & Spinal Technologies fourth quarter revenue of $1.165 billion decreased 2% as reported and 1% organic. Spine & Biologics was flat year-over-year, with low-single digit growth in Core Spine offset by low-single digit declines in Biologics. Neurosurgery grew in the low-single digits with mid-twenties growth in robotics and high-single digit growth in both navigation and powered surgical instruments on strong demand for capital equipment, offset by declines in both imaging and CSF (cerebral spinal fluid) management as a result of supply constraints.
  •  
  •   Specialty Therapies fourth quarter revenue of $684 million increased 5% as reported and 6% organic. Neurovascular increased in the low double-digits, driven by high-teens growth in hemorrhagic stroke products. Pelvic Health decreased in the mid-single digits on increased competition, and ENT increased in the mid- single digits on strength in sales of StealthStation™ ENT navigation systems.
  •  
  •   Neuromodulation fourth quarter revenue of $451 million was flat year-over-year as reported and increased 2% organic. Brain Modulation increased in the low-double digits, driven by the continued adoption of the Percept™ PC deep brain stimulation (DBS) system and SenSight™ directional DBS lead system. Pain Therapies declined in the low-single digits, with mid-single digit declines in Targeted Drug Delivery partially offset by low-single digit increases in Pain Stim on the continued adoption of the Vanta™ and Intellis™ with DTM™ SCS neurostimulators.
  •  

   Diabetes
 
Diabetes fiscal year 2022 revenue of $2.338 billion decreased 3% as reported and organic. Diabetes fourth quarter revenue of $597 million decreased 8% as reported and 5% organic. U.S. revenue declined in the high-twenties, given the absence of new product approvals. This was offset by low-double digit organic growth in non-U.S. developed markets and high-teens organic growth in emerging markets. International sales were driven by mid-single digit organic growth of durable insulin pumps, mid-teens organic growth in consumables, and low-twenties organic growth of continuous glucose monitoring (CGM) products.

 

   Guidance
 
The company today issued its fiscal year 2023 revenue growth and EPS guidance.

 

The company expects organic revenue growth in its fiscal year 2023 in the range of 4% to 5%. If recent foreign currency exchange rates hold, fiscal year 2023 revenue would be negatively affected by approximately $1.0 billion to $1.1 billion .

 

The company expects fiscal year 2023 non-GAAP EPS in the range of $5.53 to $5.65 , including an estimated 20 to 25 cent negative impact from foreign currency translation based on recent foreign currency exchange rates.

 

"We expect recent and upcoming product launches to make a difference across our businesses this coming fiscal year," said Karen Parkhill , Medtronic chief financial officer. "Supply chain, inflation, and foreign exchange are expected to create near-term pressure. Yet, we remain focused on driving our R&D investments to accelerate our growth and create large, long-term returns for our shareholders."

 

   Dividend Increase
 
The company today announced that effective May 25, 2022 , the Medtronic board of directors approved an increase in Medtronic's cash dividend for the first quarter of fiscal year 2023, raising the quarterly amount to $0.68 per ordinary share. This would translate into an annual amount of $2.72 per ordinary share, an 8% increase from the prior $2.52 . Medtronic has a long history of dividend growth, and the company is a constituent of the S&P 500 Dividend Aristocrats index. Today's announcement marks the 45th consecutive year of an increase in the dividend payment. Including today's increase, Medtronic's dividend per share has grown by 48% over the past 5 years and has grown at a 16% compounded annual growth rate over the past 45 years.

 

Medtronic has a strong track record of returning capital to its shareholders, including $5.5 billion in fiscal year 2022. The company remains committed to returning a minimum of 50 percent of its free cash flow to shareholders, primarily through dividends, and to a lesser extent, share repurchases. The dividend is payable on July 15, 2022 , to shareholders of record at the close of business on June 24, 2022 .

 

"Our substantial dividend increase reflects the confidence of our Board of Directors and executive management in Medtronic's financial strength and future earnings power," said Martha. "We've increased our dividend for the past 45 years and growing our dividend is an important component of the total return we generate for our shareholders."

 

   New Kidney Health Technology Company
 
As part of its portfolio management strategy, Medtronic announced today together with DaVita the intent to form a new, independent kidney care-focused medical device company. Medtronic will contribute its Renal Care Solutions (RCS) business to the new company, which will focus on developing a broad suite of novel kidney care products and solutions, including future home-based products, to make different dialysis treatments more accessible to patients. Additional details on the agreement are available in the joint press release issued today by Medtronic and DaVita, and in the Form 8-K that Medtronic filed today with the U.S. Securities and Exchange Commission.

 

   Webcast Information
 
Medtronic will host a webcast today, May 26 , at 8:00 a.m. EDT ( 7:00 a.m. CDT ) to provide information about its businesses for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Investor Events link at investorrelations.medtronic.com and this earnings release will be archived at news.medtronic.com . Medtronic will be live tweeting during the webcast on its Newsroom Twitter account, @Medtronic . Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Investor Events link at investorrelations.medtronic.com .

 

Medtronic plans to report its fiscal year 2023 first, second, third, and fourth quarter results on Tuesday, August 23, 2022 , November 22, 2022 , February 21, 2023 , and Thursday, May 25, 2023 , respectively. Confirmation and additional details will be provided closer to the specific event.

 

   Financial Schedules
 
The fourth quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Investor Events link at investorrelations.medtronic.com . To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here . To view the fourth quarter and fiscal year 2022 earnings presentation, click here .

 
 
                                                                                                                                                                                                                                                                                                                                                                                    
 

   MEDTRONIC PLC   

 
 

   WORLD WIDE REVENUE (1)   

 
 

  (Unaudited)  

 
 
 
 

    FOURTH QUARTER    

 
 
 
 

    YEAR-TO-DATE (2)    

 
 
 

    REPORTED    

 
 
 
 
 

    CONSTANT
CURRENCY
 
 
 

 
 
 
 

    REPORTED    

 
 
 
 
 

    CONSTANT
CURRENCY
 
 
 

 
 

    (in millions)    

 
 

  FY22  

 
 
 

  FY21  

 
 
 

  Growth  

 
 
 

  Currency
Impact (3)
 

 
 
 

  FY22  

 
 
 

  Growth  

 
 
 
 

  FY22  

 
 
 

  FY21  

 
 
 

  Growth  

 
 
 

  Currency
Impact (3)
 

 
 
 

  FY22  

 
 
 

  Growth  

 
 

    Cardiovascular    

 
 

   $    2,961   

 
 
 

   $    2,908   

 
 
 

   1.8 %   

 
 
 

   $        (84)   

 
 
 

   $    3,045   

 
 
 

   4.7 %   

 
 
 
 

   $   11,423   

 
 
 

   $   10,772   

 
 
 

   6.0 %   

 
 
 

   $        (32)   

 
 
 

   $   11,455   

 
 
 

   6.3 %   

 
 

  Cardiac Rhythm & Heart Failure  

 
 

  1,552  

 
 
 

  1,539  

 
 
 

  0.8  

 
 
 

  (43)  

 
 
 

  1,595  

 
 
 

  3.6  

 
 
 
 

  5,908  

 
 
 

  5,584  

 
 
 

  5.8  

 
 
 

  (19)  

 
 
 

  5,927  

 
 
 

  6.1  

 
 

  Structural Heart & Aortic  

 
 

  778  

 
 
 

  744  

 
 
 

  4.6  

 
 
 

  (25)  

 
 
 

  803  

 
 
 

  7.9  

 
 
 
 

  3,055  

 
 
 

  2,834  

 
 
 

  7.8  

 
 
 

  (12)  

 
 
 

  3,067  

 
 
 

  8.2  

 
 

  Coronary & Peripheral Vascular  

 
 

  631  

 
 
 

  624  

 
 
 

  1.1  

 
 
 

  (16)  

 
 
 

  647  

 
 
 

  3.7  

 
 
 
 

  2,460  

 
 
 

  2,354  

 
 
 

  4.5  

 
 
 

  (1)  

 
 
 

  2,461  

 
 
 

  4.5  

 
 

    Medical Surgical    

 
 

   2,231   

 
 
 

   2,338   

 
 
 

   (4.6)   

 
 
 

   (78)   

 
 
 

   2,309   

 
 
 

   (1.2)   

 
 
 
 

   9,141   

 
 
 

   8,737   

 
 
 

   4.6   

 
 
 

   (44)   

 
 
 

   9,185   

 
 
 

   5.1   

 
 

  Surgical Innovations  

 
 

  1,491  

 
 
 

  1,542  

 
 
 

  (3.3)  

 
 
 

  (56)  

 
 
 

  1,547  

 
 
 

  0.3  

 
 
 
 

  6,060  

 
 
 

  5,438  

 
 
 

  11.4  

 
 
 

  (31)  

 
 
 

  6,091  

 
 
 

  12.0  

 
 

  Respiratory, Gastrointestinal, & Renal  

 
 

  740  

 
 
 

  796  

 
 
 

  (7.0)  

 
 
 

  (23)  

 
 
 

  763  

 
 
 

  (4.1)  

 
 
 
 

  3,081  

 
 
 

  3,298  

 
 
 

  (6.6)  

 
 
 

  (13)  

 
 
 

  3,094  

 
 
 

  (6.2)  

 
 

    Neuroscience    

 
 

   2,299   

 
 
 

   2,295   

 
 
 

   0.2   

 
 
 

   (33)   

 
 
 

   2,332   

 
 
 

   1.6   

 
 
 
 

   8,784   

 
 
 

   8,195   

 
 
 

   7.2   

 
 
 

   3   

 
 
 

   8,781   

 
 
 

   7.2   

 
 

  Cranial & Spinal Technologies  

 
 

  1,165  

 
 
 

  1,192  

 
 
 

  (2.3)  

 
 
 

  (17)  

 
 
 

  1,182  

 
 
 

  (0.8)  

 
 
 
 

  4,456  

 
 
 

  4,288  

 
 
 

  3.9  

 
 
 

  (7)  

 
 
 

  4,463  

 
 
 

  4.1  

 
 

  Specialty Therapies  

 
 

  684  

 
 
 

  654  

 
 
 

  4.6  

 
 
 

  (8)  

 
 
 

  692  

 
 
 

  5.8  

 
 
 
 

  2,592  

 
 
 

  2,307  

 
 
 

  12.4  

 
 
 

  13  

 
 
 

  2,579  

 
 
 

  11.8  

 
 

  Neuromodulation  

 
 

  451  

 
 
 

  449  

 
 
 

  0.4  

 
 
 

  (8)  

 
 
 

  459  

 
 
 

  2.2  

 
 
 
 

  1,735  

 
 
 

  1,601  

 
 
 

  8.4  

 
 
 

  (2)  

 
 
 

  1,737  

 
 
 

  8.5  

 
 

    Diabetes    

 
 

   597   

 
 
 

   647   

 
 
 

   (7.7)   

 
 
 

   (19)   

 
 
 

   616   

 
 
 

   (4.8)   

 
 
 
 

   2,338   

 
 
 

   2,413   

 
 
 

   (3.1)   

 
 
 

   (2)   

 
 
 

   2,340   

 
 
 

   (3.0)   

 
 

    TOTAL    

 
 

   $    8,089   

 
 
 

   $    8,188   

 
 
 

   (1.2) %   

 
 
 

   $      (215)   

 
 
 

   $    8,304   

 
 
 

   1.4 %   

 
 
 
 

   $   31,686   

 
 
 

   $   30,117   

 
 
 

   5.2 %   

 
 
 

   $        (75)   

 
 
 

   $   31,761   

 
 
 

   5.5 %   

 
 
 
 
    
 
 

  (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.  

 
 

  (2) Fiscal year 2021 was a 53-week fiscal year with the extra week occurring in the first fiscal month of the first quarter and is included in reported prior year-to-date results. While it is difficult to calculate the impact of the extra week, the Company estimates the extra week benefited fiscal year 2021 year-to-date revenue by approximately $360 to $390 million.  

 
 

  (3) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.  

 
 
 

 

 
 
                                                                                                                                                                                                    
 

   MEDTRONIC PLC   

 
 

   U.S. (1)(2) REVENUE   

 
 

  (Unaudited)  

 
 
 
 

    FOURTH QUARTER    

 
 
 
 

    YEAR-TO-DATE    

 
 
 

    REPORTED    

 
 
 
 

    REPORTED    

 
 

    (in millions)    

 
 

  FY22  

 
 
 

  FY21  

 
 
 

  Growth  

 
 
 
 

  FY22  

 
 
 

  FY21  

 
 
 

  Growth  

 
 

    Cardiovascular    

 
 

   $        1,455   

 
 
 

   $        1,394   

 
 
 

   4.4 %   

 
 
 
 

   $        5,545   

 
 
 

   $        5,248   

 
 
 

   5.7 %   

 
 

  Cardiac Rhythm & Heart Failure  

 
 

  826  

 
 
 

  794  

 
 
 

  4.0  

 
 
 
 

  3,064  

 
 
 

  2,926  

 
 
 

  4.7  

 
 

  Structural Heart & Aortic  

 
 

  334  

 
 
 

  308  

 
 
 

  8.4  

 
 
 
 

  1,320  

 
 
 

  1,214  

 
 
 

  8.7  

 
 

  Coronary & Peripheral Vascular  

 
 

  295  

 
 
 

  293  

 
 
 

  0.7  

 
 
 
 

  1,162  

 
 
 

  1,108  

 
 
 

  4.9  

 
 

    Medical Surgical    

 
 

   913   

 
 
 

   973   

 
 
 

   (6.2)   

 
 
 
 

   3,862   

 
 
 

   3,650   

 
 
 

   5.8   

 
 

  Surgical Innovations  

 
 

  554  

 
 
 

  602  

 
 
 

  (8.0)  

 
 
 
 

  2,333  

 
 
 

  2,100  

 
 
 

  11.1  

 
 

  Respiratory, Gastrointestinal, & Renal  

 
 

  358  

 
 
 

  372  

 
 
 

  (3.8)  

 
 
 
 

  1,529  

 
 
 

  1,550  

 
 
 

  (1.4)  

 
 

    Neuroscience    

 
 

   1,517   

 
 
 

   1,522   

 
 
 

   (0.3)   

 
 
 
 

   5,753   

 
 
 

   5,456   

 
 
 

   5.4   

 
 

  Cranial & Spinal Technologies  

 
 

  842  

 
 
 

  846  

 
 
 

  (0.5)  

 
 
 
 

  3,170  

 
 
 

  3,064  

 
 
 

  3.5  

 
 

  Specialty Therapies  

 
 

  373  

 
 
 

  374  

 
 
 

  (0.3)  

 
 
 
 

  1,430  

 
 
 

  1,315  

 
 
 

  8.7  

 
 

  Neuromodulation  

 
 

  302  

 
 
 

  302  

 
 
 

  

 
 
 
 

  1,154  

 
 
 

  1,077  

 
 
 

  7.1  

 
 

    Diabetes    

 
 

   213   

 
 
 

   293   

 
 
 

   (27.3)   

 
 
 
 

   974   

 
 
 

   1,171   

 
 
 

   (16.8)   

 
 

    TOTAL    

 
 

   $        4,097   

 
 
 

   $        4,182   

 
 
 

   (2.0) %   

 
 
 
 

   $      16,135   

 
 
 

   $      15,526   

 
 
 

   3.9 %   

 
 
 
 
   
 
 

  (1) U.S. includes the United States and U.S. territories.  

 
 

  (2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 

   MEDTRONIC PLC   

 
 

   WORLD WIDE REVENUE: GEOGRAPHIC (1)(2)   

 
 

  (Unaudited)  

 
 
 
 

    FOURTH QUARTER    

 
 
 
 

    YEAR-TO-DATE (3)    

 
 
 

    REPORTED    

 
 
 
 
 

    CONSTANT
CURRENCY
 
 
 

 
 
 
 

    REPORTED    

 
 
 
 
 

    CONSTANT
CURRENCY
 
 
 

 
 

    (in millions)    

 
 

  FY22  

 
 
 

  FY21  

 
 
 

  Growth  

 
 
 

  Currency
Impact (4)
 

 
 
 

  FY22  

 
 
 

  Growth  

 
 
 
 

  FY22  

 
 
 

  FY21  

 
 
 

  Growth  

 
 
 

  Currency
Impact (4)
 

 
 
 

  FY22  

 
 
 

  Growth  

 
 

  U.S.  

 
 

  $    1,455  

 
 
 

  $    1,394  

 
 
 

  4.4 %  

 
 
 

  $         —  

 
 
 

  $    1,455  

 
 
 

  4.4 %  

 
 
 
 

  $    5,545  

 
 
 

  $    5,248  

 
 
 

  5.7 %  

 
 
 

  $         —  

 
 
 

  $    5,545  

 
 
 

  5.7 %  

 
 

  Non-U.S. Developed  

 
 

  980  

 
 
 

  1,012  

 
 
 

  (3.2)  

 
 
 

  (63)  

 
 
 

  1,043  

 
 
 

  3.1  

 
 
 
 

  3,866  

 
 
 

  3,752  

 
 
 

  3.0  

 
 
 

  (39)  

 
 
 

  3,905  

 
 
 

  4.1  

 
 

  Emerging Markets  

 
 

  526  

 
 
 

  501  

 
 
 

  5.0  

 
 
 

  (20)  

 
 
 

  546  

 
 
 

  9.0  

 
 
 
 

  2,012  

 
 
 

  1,773  

 
 
 

  13.5  

 
 
 

  7  

 
 
 

  2,005  

 
 
 

  13.1  

 
 

    Cardiovascular    

 
 

   2,961   

 
 
 

   2,908   

 
 
 

   1.8   

 
 
 

   (84)   

 
 
 

   3,045   

 
 
 

   4.7   

 
 
 
 

   11,423   

 
 
 

   10,772   

 
 
 

   6.0   

 
 
 

   (32)   

 
 
 

   11,455   

 
 
 

   6.3   

 
 

  U.S.  

 
 

  913  

 
 
 

  973  

 
 
 

  (6.2)  

 
 
 

  

 
 
 

  913  

 
 
 

  (6.2)  

 
 
 
 

  3,862  

 
 
 

  3,650  

 
 
 

  5.8  

 
 
 

  

 
 
 

  3,862  

 
 
 

  5.8  

 
 

  Non-U.S. Developed  

 
 

  852  

 
 
 

  895  

 
 
 

  (4.8)  

 
 
 

  (58)  

 
 
 

  910  

 
 
 

  1.7  

 
 
 
 

  3,373  

 
 
 

  3,320  

 
 
 

  1.6  

 
 
 

  (42)  

 
 
 

  3,415  

 
 
 

  2.9  

 
 

  Emerging Markets  

 
 

  466  

 
 
 

  469  

 
 
 

  (0.6)  

 
 
 

  (20)  

 
 
 

  486  

 
 
 

  3.6  

 
 
 
 

  1,905  

 
 
 

  1,766  

 
 
 

  7.9  

 
 
 

  (2)  

 
 
 

  1,907  

 
 
 

  8.0  

 
 

    Medical Surgical    

 
 

   2,231   

 
 
 

   2,338   

 
 
 

   (4.6)   

 
 
 

   (78)   

 
 
 

   2,309   

 
 
 

   (1.2)   

 
 
 
 

   9,141   

 
 
 

   8,737   

 
 
 

   4.6   

 
 
 

   (44)   

 
 
 

   9,185   

 
 
 

   5.1   

 
 

  U.S.  

 
 

  1,517  

 
 
 

  1,522  

 
 
 

  (0.3)  

 
 
 

  

 
 
 

  1,517  

 
 
 

  (0.3)  

 
 
 
 

  5,753  

 
 
 

  5,456  

 
 
 

  5.4  

 
 
 

  

 
 
 

  5,753  

 
 
 

  5.4  

 
 

  Non-U.S. Developed  

 
 

  471  

 
 
 

  477  

 
 
 

  (1.3)  

 
 
 

  (31)  

 
 
 

  502  

 
 
 

  5.2  

 
 
 
 

  1,801  

 
 
 

  1,724  

 
 
 

  4.5  

 
 
 

  (24)  

 
 
 

  1,825  

 
 
 

  5.9  

 
 

  Emerging Markets  

 
 

  311  

 
 
 

  296  

 
 
 

  5.1  

 
 
 

  (2)  

 
 
 

  313  

 
 
 

  5.7  

 
 
 
 

  1,229  

 
 
 

  1,015  

 
 
 

  21.1  

 
 
 

  27  

 
 
 

  1,202  

 
 
 

  18.4  

 
 

    Neuroscience    

 
 

   2,299   

 
 
 

   2,295   

 
 
 

   0.2   

 
 
 

   (33)   

 
 
 

   2,332   

 
 
 

   1.6   

 
 
 
 

   8,784   

 
 
 

   8,195   

 
 
 

   7.2   

 
 
 

   3   

 
 
 

   8,781   

 
 
 

   7.2   

 
 

  U.S.  

 
 

  213  

 
 
 

  293  

 
 
 

  (27.3)  

 
 
 

  

 
 
 

  213  

 
 
 

  (27.3)  

 
 
 
 

  974  

 
 
 

  1,171  

 
 
 

  (16.8)  

 
 
 

  

 
 
 

  974  

 
 
 

  (16.8)  

 
 

  Non-U.S. Developed  

 
 

  305  

 
 
 

  287  

 
 
 

  6.3  

 
 
 

  (17)  

 
 
 

  322  

 
 
 

  12.2  

 
 
 
 

  1,085  

 
 
 

  1,019  

 
 
 

  6.5  

 
 
 

  (2)  

 
 
 

  1,087  

 
 
 

  6.7  

 
 

  Emerging Markets  

 
 

  79  

 
 
 

  68  

 
 
 

  16.2  

 
 
 

  (2)  

 
 
 

  81  

 
 
 

  19.1  

 
 
 
 

  279  

 
 
 

  222  

 
 
 

  25.7  

 
 
 

  

 
 
 

  279  

 
 
 

  25.7  

 
 

    Diabetes    

 
 

   597   

 
 
 

   647   

 
 
 

   (7.7)   

 
 
 

   (19)   

 
 
 

   616   

 
 
 

   (4.8)   

 
 
 
 

   2,338   

 
 
 

   2,413   

 
 
 

   (3.1)   

 
 
 

   (2)   

 
 
 

   2,340   

 
 
 

   (3.0)   

 
 

  U.S.  

 
 

  4,097  

 
 
 

  4,182  

 
 
 

  (2.0)  

 
 
 

  

 
 
 

  4,097  

 
 
 

  (2.0)  

 
 
 
 

  16,135  

 
 
 

  15,526  

 
 
 

  3.9  

 
 
 

  

 
 
 

  16,135  

 
 
 

  3.9  

 
 

  Non-U.S. Developed  

 
 

  2,609  

 
 
 

  2,672  

 
 
 

  (2.4)  

 
 
 

  (169)  

 
 
 

  2,778  

 
 
 

  4.0  

 
 
 
 

  10,126  

 
 
 

  9,815  

 
 
 

  3.2  

 
 
 

  (107)  

 
 
 

  10,233  

 
 
 

  4.3  

 
 

  Emerging Markets  

 
 

  1,383  

 
 
 

  1,334  

 
 
 

  3.7  

 
 
 

  (45)  

 
 
 

  1,428  

 
 
 

  7.0  

 
 
 
 

  5,426  

 
 
 

  4,777  

 
 
 

  13.6  

 
 
 

  33  

 
 
 

  5,393  

 
 
 

  12.9  

 
 

    TOTAL    

 
 

   $    8,089   

 
 
 

   $    8,188   

 
 
 

   (1.2) %   

 
 
 

   $      (215)   

 
 
 

   $    8,304   

 
 
 

   1.4 %   

 
 
 
 

   $   31,686   

 
 
 

   $   30,117   

 
 
 

   5.2 %   

 
 
 

   $        (75)   

 
 
 

   $   31,761   

 
 
 

   5.5 %   

 
 
 
 
     
 
 

  (1) U.S. includes the United States and U.S. territories. Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries of Western Europe. Emerging Markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as previously defined.  

 
 

  (2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.  

 
 

  (3) Fiscal year 2021 was a 53-week fiscal year with the extra week occurring in the first fiscal month of the first quarter and is included in reported prior year-to-date results. While it is difficult to calculate the impact of the extra week, the Company estimates the extra week benefited fiscal year 2021 year-to-date revenue by approximately $360 to $390 million.  

 
 

  (4) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates.  

 
 
 

 

 
 
                                                                                                                                                                                        
 

   MEDTRONIC PLC   

 
 

   CONSOLIDATED STATEMENTS OF INCOME   

 
 

  (Unaudited)  

 
 
 
 

    Three months ended    

 
 
 

    Fiscal year ended    

 
 

    (in millions, except per share data)    

 
 

    April 29, 2022    

 
 
 

    April 30, 2021    

 
 
 

    April 29, 2022    

 
 
 

    April 30, 2021    

 
 

    Net sales    

 
 

  $              8,089  

 
 
 

  $              8,188  

 
 
 

  $            31,686  

 
 
 

  $            30,117  

 
 

    Costs and expenses:    

 
 
 
 
 
 
 
 
 

  Cost of products sold  

 
 

  2,591  

 
 
 

  2,652  

 
 
 

  10,145  

 
 
 

  10,483  

 
 

  Research and development expense  

 
 

  652  

 
 
 

  632  

 
 
 

  2,746  

 
 
 

  2,493  

 
 

  Selling, general, and administrative expense  

 
 

  2,569  

 
 
 

  2,594  

 
 
 

  10,292  

 
 
 

  10,148  

 
 

  Amortization of intangible assets  

 
 

  435  

 
 
 

  446  

 
 
 

  1,733  

 
 
 

  1,783  

 
 

  Restructuring charges, net  

 
 

  28  

 
 
 

  59  

 
 
 

  60  

 
 
 

  293  

 
 

  Certain litigation charges  

 
 

  

 
 
 

  

 
 
 

  95  

 
 
 

  118  

 
 

  Other operating expense, net  

 
 

  143  

 
 
 

  198  

 
 
 

  862  

 
 
 

  315  

 
 

    Operating profit    

 
 

  1,670  

 
 
 

  1,607  

 
 
 

  5,752  

 
 
 

  4,484  

 
 

  Other non-operating income, net  

 
 

  (74)  

 
 
 

  (102)  

 
 
 

  (318)  

 
 
 

  (336)  

 
 

  Interest expense  

 
 

  143  

 
 
 

  142  

 
 
 

  553  

 
 
 

  925  

 
 

    Income before income taxes    

 
 

  1,602  

 
 
 

  1,567  

 
 
 

  5,517  

 
 
 

  3,895  

 
 

    Income tax provision    

 
 

  110  

 
 
 

  200  

 
 
 

  456  

 
 
 

  265  

 
 

    Net income    

 
 

  1,492  

 
 
 

  1,367  

 
 
 

  5,062  

 
 
 

  3,630  

 
 

    Net income attributable to noncontrolling interests    

 
 

  (6)  

 
 
 

  (6)  

 
 
 

  (22)  

 
 
 

  (24)  

 
 

    Net income attributable to Medtronic    

 
 

  $              1,485  

 
 
 

  $              1,361  

 
 
 

  $              5,039  

 
 
 

  $              3,606  

 
 

    Basic earnings per share    

 
 

  $                 1.11  

 
 
 

  $                 1.01  

 
 
 

  $                 3.75  

 
 
 

  $                 2.68  

 
 

    Diluted earnings per share    

 
 

  $                 1.10  

 
 
 

  $                 1.00  

 
 
 

  $                 3.73  

 
 
 

  $                 2.66  

 
 

    Basic weighted average shares outstanding    

 
 

  1,337.6  

 
 
 

  1,347.3  

 
 
 

  1,342.4  

 
 
 

  1,344.9  

 
 

    Diluted weighted average shares outstanding    

 
 

  1,344.9  

 
 
 

  1,358.4  

 
 
 

  1,351.4  

 
 
 

  1,354.0  

 
 
 
 
  
 
 

    The data in the schedule above has been intentionally rounded to the nearest million, and therefore, the quarterly amounts may not sum to the fiscal year-to-date amounts.    

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (2)   

 
 

  (Unaudited)  

 
 
 
 

    Three months ended April 29, 2022    

 
 

    (in millions, except per share data)    

 
 

    Net
Sales
 
 
 

 
 
 

    Cost of
Products
Sold
 
 
 

 
 
 

    Gross
Margin
Percent
 
 
 

 
 
 

    Operating
Profit
 
 
 

 
 
 

    Operating
Profit
Percent
 
 
 

 
 
 

    Income
Before
Income
Taxes
 
 
 

 
 
 

    Net Income
attributable
to
Medtronic
 
 
 

 
 
 

    Diluted
EPS
 
 
 

 
 
 

    Effective
Tax Rate
 
 
 

 
 

    GAAP    

 
 

  $  8,089  

 
 
 

  $   2,591  

 
 
 

  68.0 %  

 
 
 

  $     1,670  

 
 
 

  20.6 %  

 
 
 

  $    1,602  

 
 
 

  $       1,485  

 
 
 

  $     1.10  

 
 
 

  6.9 %  

 
 

  Non-GAAP Adjustments:  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (3)  

 
 

  

 
 
 

  (27)  

 
 
 

  0.3  

 
 
 

  98  

 
 
 

  1.2  

 
 
 

  98  

 
 
 

  91  

 
 
 

  0.07  

 
 
 

  8.2  

 
 

  Acquisition-related items (4)  

 
 

  

 
 
 

  (5)  

 
 
 

  0.1  

 
 
 

  12  

 
 
 

  0.1  

 
 
 

  12  

 
 
 

  10  

 
 
 

  0.01  

 
 
 

  16.7  

 
 

  (Gain)/loss on minority investments (5)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  11  

 
 
 

  11  

 
 
 

  0.01  

 
 
 

  

 
 

  Medical device regulations (6)  

 
 

  

 
 
 

  (16)  

 
 
 

  0.2  

 
 
 

  32  

 
 
 

  0.4  

 
 
 

  32  

 
 
 

  29  

 
 
 

  0.02  

 
 
 

  6.3  

 
 

  Amortization of intangible assets  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  435  

 
 
 

  5.4  

 
 
 

  435  

 
 
 

  374  

 
 
 

  0.28  

 
 
 

  13.8  

 
 

  MCS costs (7)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  155  

 
 
 

  1.9  

 
 
 

  155  

 
 
 

  97  

 
 
 

  0.07  

 
 
 

  37.4  

 
 

  Certain tax adjustments, net (8)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (60)  

 
 
 

  (0.04)  

 
 
 

  

 
 

    Non-GAAP (1)    

 
 

  $  8,089  

 
 
 

  $   2,544  

 
 
 

  68.5 %  

 
 
 

  $     2,402  

 
 
 

  29.7 %  

 
 
 

  $    2,345  

 
 
 

  $       2,038  

 
 
 

  $     1.52  

 
 
 

  12.8 %  

 
 

  Currency impact  

 
 

  215  

 
 
 

  71  

 
 
 

  

 
 
 

  (9)  

 
 
 

  (0.9)  

 
 
 
 
 
 
 

  

 
 
 
 

    Currency Adjusted    

 
 

  $  8,304  

 
 
 

  $   2,615  

 
 
 

  68.5 %  

 
 
 

  $     2,393  

 
 
 

  28.8 %  

 
 
 
 
 
 
 

  $     1.52  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

    Three months ended April 30, 2021    

 
 

    (in millions, except per share data)    

 
 

    Net
Sales
 
 
 

 
 
 

    Cost of
Products
Sold
 
 
 

 
 
 

    Gross
Margin
Percent
 
 
 

 
 
 

    Operating
Profit
 
 
 

 
 
 

    Operating
Profit
Percent
 
 
 

 
 
 

    Income
Before
Income
Taxes
 
 
 

 
 
 

    Net Income
attributable
to
Medtronic
 
 
 

 
 
 

    Diluted
EPS
 
 
 

 
 
 

    Effective
Tax Rate
 
 
 

 
 

    GAAP    

 
 

  $  8,188  

 
 
 

  $   2,652  

 
 
 

  67.6 %  

 
 
 

  $     1,607  

 
 
 

  19.6 %  

 
 
 

  $    1,567  

 
 
 

  $       1,361  

 
 
 

  $     1.00  

 
 
 

  12.8 %  

 
 

  Non-GAAP Adjustments:  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (3)  

 
 

  

 
 
 

  (33)  

 
 
 

  0.4  

 
 
 

  151  

 
 
 

  1.8  

 
 
 

  151  

 
 
 

  131  

 
 
 

  0.10  

 
 
 

  13.2  

 
 

  Acquisition-related items (1) (4)  

 
 

  

 
 
 

  (5)  

 
 
 

  0.1  

 
 
 

  18  

 
 
 

  0.2  

 
 
 

  18  

 
 
 

  16  

 
 
 

  0.01  

 
 
 

  11.1  

 
 

  (Gain)/loss on minority investments (5)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (34)  

 
 
 

  (34)  

 
 
 

  (0.03)  

 
 
 

  

 
 

  Medical device regulations (6)  

 
 

  

 
 
 

  (13)  

 
 
 

  0.2  

 
 
 

  24  

 
 
 

  0.3  

 
 
 

  24  

 
 
 

  20  

 
 
 

  0.01  

 
 
 

  16.7  

 
 

  Impairment charges (9)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  76  

 
 
 

  0.9  

 
 
 

  76  

 
 
 

  68  

 
 
 

  0.05  

 
 
 

  10.5  

 
 

  Amortization of intangible assets  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  446  

 
 
 

  5.4  

 
 
 

  446  

 
 
 

  377  

 
 
 

  0.28  

 
 
 

  15.5  

 
 

  Certain tax adjustments, net (8)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  90  

 
 
 

  0.07  

 
 
 

  

 
 

    Non-GAAP (1)    

 
 

  $  8,188  

 
 
 

  $   2,601  

 
 
 

  68.2 %  

 
 
 

  $     2,322  

 
 
 

  28.4 %  

 
 
 

  $    2,248  

 
 
 

  $       2,029  

 
 
 

  $     1.49  

 
 
 

  9.6 %  

 
 
 
 
           
 
 

  See description of non-GAAP financial measures contained in the press release dated May 26, 2022.  

 
 

  (1) Starting with the quarter ended April 29, 2022, the Company will no longer adjust non-GAAP financial measures for certain license payments for, or acquisitions of, technology not approved by regulators due to recent industry guidance from the U.S. Securities and Exchange Commission. Historical non-GAAP financial measures presented in our earnings release have been recast for comparability. The impact of this change is a decrease in non-GAAP net income and diluted EPS of $9 million and $0.01, respectively, for the three months ended April 30, 2021. There was no impact to the three months ended April 29, 2022.  

 
 

  (2) The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.  

 
 

  (3) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.  

 
 

  (4) The charges primarily include business combination costs, and specifically for the three months ended April 29, 2022, changes in fair value of contingent consideration.  

 
 

  (5) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.  

 
 

  (6) The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses, which are expected to be substantially complete by the end of fiscal year 2023.  

 
 

  (7) The charges relate to incremental commitments and obligations, including patient support obligations and other remediation costs, associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory Support Operating Unit (MCS).  

 
 

  (8) The certain adjustments, net relate to amortization on previously established deferred tax assets from intercompany intellectual property transactions and impacts from tax rate changes and tax basis adjustments.  

 
 

  (9) These charges relate to the abandonment of certain intangible assets in our Neuroscience segment.  

 
 
 

 

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (2)   

 
 

  (Unaudited)  

 
 
 
 

    Fiscal year ended April 29, 2022    

 
 

    (in millions, except per share data)    

 
 

    Net Sales    

 
 
 

    Cost of
Products
Sold
 
 
 

 
 
 

    Gross
Margin
Percent
 
 
 

 
 
 

    Operating
Profit
 
 
 

 
 
 

    Operating
Profit
Percent
 
 
 

 
 
 

    Income
Before
Income
Taxes
 
 
 

 
 
 

    Net Income
attributable
to Medtronic
 
 
 

 
 
 

    Diluted
EPS
 
 
 

 
 
 

    Effective
Tax Rate
 
 
 

 
 

    GAAP    

 
 

  $ 31,686  

 
 
 

  $  10,145  

 
 
 

  68.0 %  

 
 
 

  $     5,752  

 
 
 

  18.2 %  

 
 
 

  $    5,517  

 
 
 

  $         5,039  

 
 
 

  $     3.73  

 
 
 

  8.3 %  

 
 

  Non-GAAP Adjustments:  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (3)  

 
 

  

 
 
 

  (117)  

 
 
 

  0.4  

 
 
 

  335  

 
 
 

  1.1  

 
 
 

  335  

 
 
 

  281  

 
 
 

  0.21  

 
 
 

  16.1  

 
 

  Acquisition-related items (1) (4)  

 
 

  

 
 
 

  (19)  

 
 
 

  0.1  

 
 
 

  58  

 
 
 

  0.2  

 
 
 

  58  

 
 
 

  30  

 
 
 

  0.02  

 
 
 

  48.3  

 
 

  Certain litigation charges  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  95  

 
 
 

  0.3  

 
 
 

  95  

 
 
 

  78  

 
 
 

  0.06  

 
 
 

  17.9  

 
 

  (Gain)/loss on minority investments (5)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (12)  

 
 
 

  (9)  

 
 
 

  (0.01)  

 
 
 

  

 
 

  Medical device regulations (6)  

 
 

  

 
 
 

  (55)  

 
 
 

  0.2  

 
 
 

  102  

 
 
 

  0.3  

 
 
 

  102  

 
 
 

  86  

 
 
 

  0.06  

 
 
 

  15.7  

 
 

  Amortization of intangible assets  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  1,733  

 
 
 

  5.5  

 
 
 

  1,733  

 
 
 

  1,467  

 
 
 

  1.09  

 
 
 

  15.3  

 
 

  MCS impairment / costs (7)  

 
 

  

 
 
 

  (58)  

 
 
 

  0.2  

 
 
 

  881  

 
 
 

  2.8  

 
 
 

  881  

 
 
 

  661  

 
 
 

  0.49  

 
 
 

  25.0  

 
 

  Certain tax adjustments, net (8)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (50)  

 
 
 

  (0.04)  

 
 
 

  

 
 

    Prior to recasting IPR&D charges    

 
 

  $ 31,686  

 
 
 

  $   9,897  

 
 
 

  68.8 %  

 
 
 

  $     8,957  

 
 
 

  28.3 %  

 
 
 

  $    8,710  

 
 
 

  $         7,583  

 
 
 

  $     5.61  

 
 
 

  12.7 %  

 
 

  Impact of recast IPR&D charges (1)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (101)  

 
 
 

  (0.3)  

 
 
 

  (101)  

 
 
 

  (78)  

 
 
 

  (0.06)  

 
 
 

  22.8  

 
 

    Non-GAAP (1)    

 
 

  $ 31,686  

 
 
 

  $   9,897  

 
 
 

  68.8 %  

 
 
 

  $     8,856  

 
 
 

  27.9 %  

 
 
 

  $    8,609  

 
 
 

  $         7,505  

 
 
 

  $     5.55  

 
 
 

  12.6 %  

 
 

  Currency impact  

 
 

  75  

 
 
 

  131  

 
 
 

  (0.4)  

 
 
 

  (157)  

 
 
 

  (0.5)  

 
 
 
 
 
 
 

  (0.10)  

 
 
 
 

    Currency Adjusted    

 
 

  $ 31,761  

 
 
 

  $  10,028  

 
 
 

  68.4 %  

 
 
 

  $     8,699  

 
 
 

  27.4 %  

 
 
 
 
 
 
 

  $     5.45  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

    Fiscal year ended April 30, 2021    

 
 

    (in millions, except per share data)    

 
 

    Net Sales    

 
 
 

    Cost of
Products
Sold
 
 
 

 
 
 

    Gross
Margin
Percent
 
 
 

 
 
 

    Operating
Profit
 
 
 

 
 
 

    Operating
Profit
Percent
 
 
 

 
 
 

    Income
Before
Income
Taxes
 
 
 

 
 
 

    Net Income
attributable
to Medtronic
 
 
 

 
 
 

    Diluted
EPS
 
 
 

 
 
 

    Effective
Tax Rate
 
 
 

 
 

    GAAP    

 
 

  $ 30,117  

 
 
 

  $  10,483  

 
 
 

  65.2 %  

 
 
 

  $     4,484  

 
 
 

  14.9 %  

 
 
 

  $    3,895  

 
 
 

  $         3,606  

 
 
 

  $     2.66  

 
 
 

  6.8 %  

 
 

  Non-GAAP Adjustments:  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (3)  

 
 

  

 
 
 

  (128)  

 
 
 

  0.4  

 
 
 

  617  

 
 
 

  2.0  

 
 
 

  617  

 
 
 

  489  

 
 
 

  0.36  

 
 
 

  20.7  

 
 

  Acquisition-related items (1) (4)  

 
 

  

 
 
 

  (15)  

 
 
 

  

 
 
 

  (15)  

 
 
 

  

 
 
 

  (15)  

 
 
 

  4  

 
 
 

  

 
 
 

  126.7  

 
 

  Certain litigation charges  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  118  

 
 
 

  0.4  

 
 
 

  118  

 
 
 

  95  

 
 
 

  0.07  

 
 
 

  19.5  

 
 

  (Gain)/loss on minority investments (5)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (61)  

 
 
 

  (57)  

 
 
 

  (0.04)  

 
 
 

  

 
 

  Impairment charges (9)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  76  

 
 
 

  0.3  

 
 
 

  76  

 
 
 

  68  

 
 
 

  0.05  

 
 
 

  10.5  

 
 

  Medical device regulations (6)  

 
 

  

 
 
 

  (45)  

 
 
 

  0.1  

 
 
 

  83  

 
 
 

  0.3  

 
 
 

  83  

 
 
 

  68  

 
 
 

  0.05  

 
 
 

  18.1  

 
 

  Debt tender premium and other charges (10)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  308  

 
 
 

  248  

 
 
 

  0.18  

 
 
 

  19.5  

 
 

  Amortization of intangible assets  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  1,783  

 
 
 

  5.9  

 
 
 

  1,783  

 
 
 

  1,500  

 
 
 

  1.11  

 
 
 

  15.9  

 
 

  Certain tax adjustments, net (11)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (41)  

 
 
 

  (0.03)  

 
 
 

  

 
 

    Non-GAAP (1)    

 
 

  $ 30,117  

 
 
 

  $  10,295  

 
 
 

  65.8 %  

 
 
 

  $     7,146  

 
 
 

  23.7 %  

 
 
 

  $    6,804  

 
 
 

  $         5,980  

 
 
 

  $     4.42  

 
 
 

  11.8 %  

 
 
 
 
             
 
 

  See description of non-GAAP financial measures contained in the press release dated May 26, 2022.  

 
 

  (1) Starting with the quarter ended April 29, 2022, the Company will no longer adjust non-GAAP financial measures for certain license payments for, or acquisitions of, technology not approved by regulators due to recent industry guidance from the U.S. Securities and Exchange Commission. Historical non-GAAP financial measures presented in our earnings release have been recast for comparability. The impact of this change for the fiscal year ended April 29, 2022 is a decrease in non-GAAP net income and diluted EPS of $78 million and $0.06, respectively, including (a) $70 million and $0.05, respectively, for the first quarter of fiscal year 2022, and (b) $8 million and $0.01, respectively, for the third quarter of fiscal year 2022. The impact of this change for the fiscal year ended April 30, 2021 is a decrease in non-GAAP net income and diluted EPS of $25 million and $0.02, respectively, including (a) $8 million and $0.01, respectively, for both the first and second quarter of fiscal year 2021, and (b) $9 million and $0.01, respectively, for the fourth quarter of fiscal year 2021. There was no currency impact to the recast in-process research and development (IPR&D) charges.  

 
 

  (2) The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum.  

 
 

  (3) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.  

 
 

  (4) The charges primarily include business combination costs, changes in fair value of contingent consideration, and specifically for the fiscal year ended April 30, 2021 changes in amounts accrued for certain contingent liabilities for recent acquisitions.  

 
 

  (5) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.  

 
 

  (6) The charges represent estimated incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses, which are expected to be substantially complete by the end of fiscal year 2023.  

 
 

  (7) The charges relate to the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory Support Operating Unit (MCS). The charges included $515 million of non-cash impairments, primarily related to $409 million of intangible asset impairments, as well as $366 million for commitments and obligations in connection with the decision, including patient support obligations, restructuring, and other associated costs. Medtronic is committed to serving the needs of the approximately 3,500 patients currently implanted with the HVAD System.  

 
 

  (8) The net benefit primarily relates to the deferred tax impact associated with a step up in tax basis for Swiss Cantonal purposes and a change in tax rates on deferred taxes associated with intellectual property, which are partially offset by the amortization on previously established deferred tax assets from intercompany intellectual property transactions and a charge related to a change in the Company's permanent reinvestment assertion on certain historical earnings.  

 
 

  (9) The charges relate to the abandonment of certain intangible assets in our Neuroscience segment.  

 
 

  (10) The charges relate to the early redemption of approximately $6.0 billion of debt.  

 
 

  (11) The net benefit primarily relates to the finalization of an audit at the IRS Appellate level for fiscal years 2012 through 2014 and the capitalization of certain research and development costs for U.S. income tax purposes, which are partially offset by the impact of an intercompany sale of assets, and a tax basis adjustment and amortization of previously established deferred tax assets from intercompany intellectual property transactions.  

 
 
 

 

 
 
                                                                                                                                                                                      
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (2)   

 
 

  (Unaudited)  

 
 
 
 

    Three months ended April 29, 2022    

 
 

    (in millions)    

 
 

    Net Sales    

 
 
 

    SG&A
Expense
 
 
 

 
 
 

    SG&A
Expense as
a % of Net
Sales
 
 
 

 
 
 

    R&D
Expense
 
 
 

 
 
 

    R&D
Expense
as a % of
Net Sales
 
 
 

 
 
 

    Other
Operating
(Income)
Expense,
net
 
 
 

 
 
 

    Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales
 
 
 

 
 
 

    Other Non-
Operating
Income, net
 
 
 

 
 

    GAAP    

 
 

  $      8,089  

 
 
 

  $     2,569  

 
 
 

  31.8 %  

 
 
 

  $       652  

 
 
 

  8.1 %  

 
 
 

  $         143  

 
 
 

  1.8 %  

 
 
 

  $            (74)  

 
 

  Non-GAAP Adjustments:  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (3)  

 
 

  

 
 
 

  (44)  

 
 
 

  (0.5)  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 

  Acquisition-related items (4)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (7)  

 
 
 

  (0.1)  

 
 
 

  

 
 

  Medical device regulations (5)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (15)  

 
 
 

  (0.2)  

 
 
 

  

 
 
 

  

 
 
 

  

 
 

  MCS costs (6)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (155)  

 
 
 

  (1.9)  

 
 
 

  

 
 

  (Gain)/loss on minority investments (7)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (11)  

 
 

    Non-GAAP (1)    

 
 

  $      8,089  

 
 
 

  $     2,525  

 
 
 

  31.2 %  

 
 
 

  $       637  

 
 
 

  7.9 %  

 
 
 

  $          (19)  

 
 
 

  (0.2) %  

 
 
 

  $            (85)  

 
 

  Currency impact  

 
 

  215  

 
 
 

  47  

 
 
 

  (0.2)  

 
 
 

  1  

 
 
 

  (0.2)  

 
 
 

  104  

 
 
 

  1.2  

 
 
 

  (2)  

 
 

    Currency Adjusted    

 
 

  $      8,304  

 
 
 

  $     2,572  

 
 
 

  31.0 %  

 
 
 

  $       638  

 
 
 

  7.7 %  

 
 
 

  $           85  

 
 
 

  1.0 %  

 
 
 

  $            (87)  

 
 
 

 

 
 
                                                                                                                                                                                  
 
 

    Fiscal year ended April 29, 2022    

 
 

    (in millions)    

 
 

    Net Sales    

 
 
 

    SG&A
Expense
 
 
 

 
 
 

    SG&A
Expense as
a % of
Net Sales
 
 
 

 
 
 

    R&D
Expense
 
 
 

 
 
 

    R&D
Expense
as a % of
Net Sales
 
 
 

 
 
 

    Other
Operating
(Income)
Expense,
net
 
 
 

 
 
 

    Other
Operating
(Inc.)/Exp.,
net as a % of
Net Sales
 
 
 

 
 
 

    Other Non-
Operating
Income, net
 
 
 

 
 

    GAAP    

 
 

  $    31,686  

 
 
 

  $   10,292  

 
 
 

  32.5 %  

 
 
 

  $    2,746  

 
 
 

  8.7 %  

 
 
 

  $         862  

 
 
 

  2.7 %  

 
 
 

  $          (318)  

 
 

  Non-GAAP Adjustments:  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Restructuring and associated costs (3)  

 
 

  

 
 
 

  (158)  

 
 
 

  (0.5)  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 

  Acquisition-related items (1) (4)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  60  

 
 
 

  0.2  

 
 
 

  

 
 

  Medical device regulations (5)  

 
 

  

 
 
 

  (2)  

 
 
 

  

 
 
 

  (45)  

 
 
 

  (0.1)  

 
 
 

  

 
 
 

  

 
 
 

  

 
 

  MCS impairment / costs (6)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  (823)  

 
 
 

  (2.6)  

 
 
 

  

 
 

  (Gain)/loss on minority investments (7)  

 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  

 
 
 

  12  

 
 

    Non-GAAP (1)    

 
 

  $    31,686  

 
 
 

  $   10,133  

 
 
 

  32.0 %  

 
 
 

  $    2,701  

 
 
 

  8.5 %  

 
 
 

  $           99  

 
 
 

  0.3 %  

 
 
 

  $          (306)  

 
 

  Currency impact  

 
 

  75  

 
 
 

  1  

 
 
 

  (0.1)  

 
 
 

  (7)  

 
 
 

  

 
 
 

  108  

 
 
 

  0.4  

 
 
 

  (1)  

 
 

    Currency Adjusted    

 
 

  $    31,761  

 
 
 

  $   10,134  

 
 
 

  31.9 %  

 
 
 

  $    2,694  

 
 
 

  8.5 %  

 
 
 

  $         207  

 
 
 

  0.7 %  

 
 
 

  $          (307)  

 
 
 
 
         
 
 

  See description of non-GAAP financial measures contained in the press release dated May 26, 2022.  

 
 

  (1) Starting with the quarter ended April 29, 2022, the Company will no longer adjust non-GAAP financial measures for certain license payments for, or acquisitions of, technology not approved by regulators due to recent industry guidance from the U.S. Securities and Exchange Commission. Historical non-GAAP financial measures presented in our earnings release have been recast for comparability. The impact of this change is a decrease in non-GAAP net income and diluted EPS of $78 million and $0.06, respectively, for the fiscal year ended April 29, 2022. There was no impact to the three months ended April 29, 2022.  

 
 

  (2) The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.  

 
 

  (3) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses.  

 
 

  (4) The charges primarily include business combination costs and changes in fair value of contingent consideration.  

 
 

  (5) The charges represent estimated incremental costs of complying with the new European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses, which are expected to be substantially complete by the end of fiscal year 2023.  

 
 

  (6) The charges relate to the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System within the Mechanical Circulatory Support Operating Unit (MCS). The charges included $515 million of non-cash impairments, primarily related to $409 million of intangible asset impairments, as well as $211 million in the first quarter of fiscal year 2022 and $155 million in the fourth quarter of fiscal year 2022 for commitments and obligations in connection with the decision, including customer support obligations, restructuring, and other associated costs. Medtronic is committed to serving the needs of the approximately 3,500 patients currently implanted with the HVAD System.  

 
 

  (7) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.  

 
 
 

 

 
 
                              
 

   MEDTRONIC PLC   

 
 

   GAAP TO NON-GAAP RECONCILIATIONS (1)   

 
 

  (Unaudited)  

 
 
 
 

    Fiscal Year    

 
 

    (in millions)    

 
 

   2022   

 
 
 

   2021   

 
 
 

   2020   

 
 

    Net cash provided by operating activities    

 
 

  $                      7,346  

 
 
 

  $                      6,240  

 
 
 

  $                      7,234  

 
 

  Additions to property, plant, and equipment  

 
 

  (1,368)  

 
 
 

  (1,355)  

 
 
 

  (1,213)  

 
 

    Free Cash Flow (2)    

 
 

  $                      5,978  

 
 
 

  $                      4,885  

 
 
 

  $                      6,021  

 
 
 
 
    
 
 

  See description of non-GAAP financial measures contained in the press release dated May 26, 2022.  

 
 

  (1) The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.  

 
 

  (2) Free cash flow represents operating cash flows less property, plant, and equipment additions.  

 
 
 

 

 
 
                                                                                                                                                                                                       
 

   MEDTRONIC PLC   

 
 

   CONSOLIDATED BALANCE SHEETS   

 
 

  (Unaudited)  

 
 
 

    (in millions)    

 
 
 

    April 29, 2022    

 
 
 

    April 30, 2021    

 
 

     ASSETS     

 
 
 
 
 
 

    Current assets:    

 
 
 
 
 
 

  Cash and cash equivalents  

 
 
 

  $               3,714  

 
 
 

  $               3,593  

 
 

  Investments  

 
 
 

  6,859  

 
 
 

  7,224  

 
 

  Accounts receivable, less allowances and credit losses of $230 and $241, respectively  

 
 
 

  5,551  

 
 
 

  5,462  

 
 

  Inventories, net  

 
 
 

  4,616  

 
 
 

  4,313  

 
 

  Other current assets  

 
 
 

  2,318  

 
 
 

  1,955  

 
 

    Total current assets    

 
 
 

  23,059  

 
 
 

  22,548  

 
 

    Property, plant, and equipment, net    

 
 
 

  5,413  

 
 
 

  5,221  

 
 

    Goodwill    

 
 
 

  40,502  

 
 
 

  41,961  

 
 

    Other intangible assets, net    

 
 
 

  15,595  

 
 
 

  17,740  

 
 

    Tax assets    

 
 
 

  3,403  

 
 
 

  3,169  

 
 

    Other assets    

 
 
 

  3,008  

 
 
 

  2,443  

 
 

    Total assets    

 
 
 

  $             90,981  

 
 
 

  $             93,083  

 
 

     LIABILITIES AND EQUITY     

 
 
 
 
 
 

    Current liabilities:    

 
 
 
 
 
 

  Current debt obligations  

 
 
 

  $               3,742  

 
 
 

  $                     11  

 
 

  Accounts payable  

 
 
 

  2,276  

 
 
 

  2,106  

 
 

  Accrued compensation  

 
 
 

  2,121  

 
 
 

  2,482  

 
 

  Accrued income taxes  

 
 
 

  704  

 
 
 

  435  

 
 

  Other accrued expenses  

 
 
 

  3,551  

 
 
 

  3,475  

 
 

    Total current liabilities    

 
 
 

  12,394  

 
 
 

  8,509  

 
 

    Long-term debt    

 
 
 

  20,372  

 
 
 

  26,378  

 
 

    Accrued compensation and retirement benefits    

 
 
 

  1,113  

 
 
 

  1,557  

 
 

    Accrued income taxes    

 
 
 

  2,087  

 
 
 

  2,251  

 
 

    Deferred tax liabilities    

 
 
 

  884  

 
 
 

  1,028  

 
 

    Other liabilities    

 
 
 

  1,410  

 
 
 

  1,756  

 
 

    Total liabilities    

 
 
 

  38,260  

 
 
 

  41,481  

 
 

    Commitments and contingencies    

 
 
 
 
 
 

    Shareholders' equity:    

 
 
 
 
 
 

  Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,330,743,395
and 1,345,400,671 shares issued and outstanding, respectively
 

 
 
 

  

 
 
 

  

 
 

  Additional paid-in capital  

 
 
 

  24,566  

 
 
 

  26,319  

 
 

  Retained earnings  

 
 
 

  30,250  

 
 
 

  28,594  

 
 

  Accumulated other comprehensive loss  

 
 
 

  (2,265)  

 
 
 

  (3,485)  

 
 

    Total shareholders' equity    

 
 
 

  52,551  

 
 
 

  51,428  

 
 

  Noncontrolling interests  

 
 
 

  171  

 
 
 

  174  

 
 

    Total equity    

 
 
 

  52,722  

 
 
 

  51,602  

 
 

    Total liabilities and equity    

 
 
 

  $             90,981  

 
 
 

  $             93,083  

 
 
 
 
  
 
 

    The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.    

 
 
 

 

 
 
                                                                                                                                                                                                                                                                        
 

   MEDTRONIC PLC   

 
 

   CONSOLIDATED STATEMENTS OF CASH FLOWS   

 
 

  (Unaudited)  

 
 
 
 

    Fiscal Year    

 
 

    (in millions)    

 
 

   2022   

 
 
 

   2021   

 
 
 

   2020   

 
 

    Operating Activities:    

 
 
 
 
 
 
 

  Net income  

 
 

  $           5,062  

 
 
 

  $           3,630  

 
 
 

  $           4,806  

 
 

  Adjustments to reconcile net income to net cash provided by operating activities:  

 
 
 
 
 
 
 

  Depreciation and amortization  

 
 

  2,707  

 
 
 

  2,702  

 
 
 

  2,663  

 
 

  Provision for credit losses  

 
 

  58  

 
 
 

  128  

 
 
 

  99  

 
 

  Deferred income taxes  

 
 

  (604)  

 
 
 

  (422)  

 
 
 

  (1,315)  

 
 

  Stock-based compensation  

 
 

  359  

 
 
 

  344  

 
 
 

  297  

 
 

  Loss on debt extinguishment  

 
 

  

 
 
 

  308  

 
 
 

  406  

 
 

  Asset impairment charges  

 
 

  515  

 
 
 

  

 
 
 

  

 
 

  Other, net  

 
 

  138  

 
 
 

  251  

 
 
 

  217  

 
 

  Change in operating assets and liabilities, net of acquisitions and divestitures:  

 
 
 
 
 
 
 

  Accounts receivable, net  

 
 

  (477)  

 
 
 

  (761)  

 
 
 

  1,291  

 
 

  Inventories, net  

 
 

  (560)  

 
 
 

  78  

 
 
 

  (577)  

 
 

  Accounts payable and accrued liabilities  

 
 

  213  

 
 
 

  531  

 
 
 

  (44)  

 
 

  Other operating assets and liabilities  

 
 

  (65)  

 
 
 

  (549)  

 
 
 

  (609)  

 
 

    Net cash provided by operating activities    

 
 

  7,346  

 
 
 

  6,240  

 
 
 

  7,234  

 
 

    Investing Activities:    

 
 
 
 
 
 
 

  Acquisitions, net of cash acquired  

 
 

  (91)  

 
 
 

  (994)  

 
 
 

  (488)  

 
 

  Additions to property, plant, and equipment  

 
 

  (1,368)  

 
 
 

  (1,355)  

 
 
 

  (1,213)  

 
 

  Purchases of investments  

 
 

  (9,882)  

 
 
 

  (11,808)  

 
 
 

  (11,039)  

 
 

  Sales and maturities of investments  

 
 

  9,692  

 
 
 

  11,345  

 
 
 

  9,574  

 
 

  Other investing activities, net  

 
 

  (10)  

 
 
 

  (54)  

 
 
 

  (37)  

 
 

    Net cash used in investing activities    

 
 

  (1,659)  

 
 
 

  (2,866)  

 
 
 

  (3,203)  

 
 

    Financing Activities:    

 
 
 
 
 
 
 

  Change in current debt obligations, net  

 
 

  

 
 
 

  (311)  

 
 
 

  (17)  

 
 

  Proceeds from short-term borrowings (maturities greater than 90 days)  

 
 

  

 
 
 

  2,789  

 
 
 

  

 
 

  Repayments from short-term borrowings (maturities greater than 90 days)  

 
 

  

 
 
 

  (2,853)  

 
 
 

  

 
 

  Issuance of long-term debt  

 
 

  

 
 
 

  7,172  

 
 
 

  5,568  

 
 

  Payments on long-term debt  

 
 

  (1)  

 
 
 

  (7,367)  

 
 
 

  (6,110)  

 
 

  Dividends to shareholders  

 
 

  (3,383)  

 
 
 

  (3,120)  

 
 
 

  (2,894)  

 
 

  Issuance of ordinary shares  

 
 

  429  

 
 
 

  474  

 
 
 

  662  

 
 

  Repurchase of ordinary shares  

 
 

  (2,544)  

 
 
 

  (652)  

 
 
 

  (1,326)  

 
 

  Other financing activities  

 
 

  163  

 
 
 

  (268)  

 
 
 

  (81)  

 
 

    Net cash used in financing activities    

 
 

  (5,336)  

 
 
 

  (4,136)  

 
 
 

  (4,198)  

 
 

  Effect of exchange rate changes on cash and cash equivalents  

 
 

  (231)  

 
 
 

  215  

 
 
 

  (86)  

 
 

    Net change in cash and cash equivalents    

 
 

  121  

 
 
 

  (547)  

 
 
 

  (253)  

 
 

  Cash and cash equivalents at beginning of period  

 
 

  3,593  

 
 
 

  4,140  

 
 
 

  4,393  

 
 

    Cash and cash equivalents at end of period    

 
 

  $           3,714  

 
 
 

  $           3,593  

 
 
 

  $           4,140  

 
 

    Supplemental Cash Flow Information    

 
 
 
 
 
 
 

  Cash paid for:  

 
 
 
 
 
 
 

  Income taxes  

 
 

  $               996  

 
 
 

  $           1,250  

 
 
 

  $               878  

 
 

  Interest  

 
 

  540  

 
 
 

  582  

 
 
 

  643  

 
 
 
 
  
 
 

    The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.    

 
 
 

   About Medtronic
 
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

 

   FORWARD LOOKING STATEMENTS
 
  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation and general economic conditions and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company, as filed with the U.S. Securities and Exchange Commission. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances.  

 

   NON-GAAP FINANCIAL MEASURES
 
  This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly and annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2021.  

 

  Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety.   Starting with the quarter ended April 29, 2022 , the Company will no longer adjust non-GAAP financial measures for certain license payments for, or acquisitions of, technology not approved by regulators. Historical non-GAAP financial measures have been recast for comparability.   Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release.  

 

  Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions or divestitures. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.  

 
 
          
 

   Contacts:   

 
 
 
 
 

  Erika Winkels  

 
 

  Ryan Weispfenning  

 
 

  Public Relations  

 
 

  Investor Relations  

 
 

  +1-763-526-8478  

 
 

  +1-763-505-4626  

 
 
 

 

 

 

 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-reports-full-year-and-fourth-quarter-fiscal-year-2022-financial-results-announces-8-dividend-increase-301555535.html  

 

SOURCE Medtronic plc

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/May2022/26/c5144.html  

 
 

News Provided by Canada Newswire via QuoteMedia

MDT
The Conversation (0)
Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

Pine Cliff Energy Ltd. Announces First Quarter 2024 Results and Information Regarding the Annual Meeting of Shareholders

 

Pine Cliff Energy Ltd. (TSX: PNE) ("Pine Cliff" or the "Company") announces its first quarter 2024 financial and operating results, an operational update and information regarding the annual meeting of shareholders.

 

First Quarter 2024 Results

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Canadian Natural Resources Limited Announces 2024 First Quarter Results

 

Canadian Natural's (TSX: CNQ) (NYSE: CNQ) President, Scott Stauth, commented on the Company's first quarter results, "Canadian Natural is a world class company and during our 35 years of operations, we've delivered significant value, including recently reaching a position where, commencing in 2024, we are returning 100% of our free cash flow to our shareholders. Crude oil price forecasts have strengthened for the remainder of 2024, including improvements in West Texas Intermediate ("WTI"), Western Canadian Select ("WCS") and Synthetic Crude Oil ("SCO") pricing over those prices experienced in the first quarter of 2024, driving significant targeted free cash flow generation going forward.

 

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. Announces Appointment of Officers, Declares Monthly Dividend for May 31, 2024 and First Quarter 2024 Webcast Details

Pine Cliff Energy Ltd. (TSX: PNE) (OTCQX: PIFYF) ("Pine Cliff" or the "Company") is pleased to announce the appointments of Mr. Daniel Keenan P. Eng to the position of Vice President Exploitation and Mr. Austin Nieuwdorp CA, CPA to the position of Vice President Finance and Controller both effective May 1, 2024.

Mr. Keenan became part of Pine Cliff in 2016. He holds a Bachelor of Mechanical Engineering Degree from the University of Victoria obtained in 2001. Throughout his 20-year career, he has taken on increasingly challenging roles in exploitation, production operations and facilities engineering, culminating in his most recent position as Pine Cliff's Manager of Exploitation. Notably, Mr. Keenan has played a pivotal role in identifying and expanding Pine Cliff's asset portfolio and drilling opportunities, showcasing his leadership and strategic vision.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

ATCO Ltd. to Share Strategic Update at Annual General Meeting on May 15, 2024

 
 

ATCO Ltd. (TSX: ACO.X) (TSX: ACO.Y)

 
 

  2024 ATCO AGM (CNW Group/ATCO Ltd.) 

 

ATCO Ltd. (ATCO) will hold its 57th Annual General Meeting of share owners at 10 a.m. MDT on Wednesday , May 15, 2024. In addition to the formal business of the meeting, attendees will hear management's view of ATCO's full year 2023 and first quarter 2024 operational and financial performance.

 

At this year's meeting, members of the ATCO executive leadership team will also outline growth strategies and goals for ATCO Structures, ATCO EnPower and ATCO Energy Systems.

 

Attendees will hear from:

 
  •    Nancy Southern , Chair & Chief Executive Officer  
  •  
  •    Katie Patrick , Executive Vice President, Chief Financial & Investment Officer  
  •  
  •    Adam Beattie , President, ATCO Structures  
  •  
  •    Bob Myles , Chief Operating Officer, ATCO EnPower  
  •  
  •    Wayne Stensby , Chief Operating Officer, ATCO Energy Systems  
  •  

Share owners and interested parties can view the meeting virtually using Microsoft Teams via this link using a web browser (Chrome, Safari, Edge or Firefox) on a smartphone, tablet or computer. Using Internet Explorer is not recommended as it is no longer supported and may not function properly.

 

Attendees who are share owners or proxyholders wishing to vote their shares should review the information contained in the ATCO Management Proxy Circular dated March 11, 2024 , beginning on page one.

 

As a global enterprise ATCO Ltd. and its subsidiary and affiliate companies have approximately 20,000 employees and assets of $25 billion . ATCO is committed to future prosperity by working to meet the world's essential energy, housing, security and transportation challenges. ATCO Structures designs, builds and delivers products to service the essential need for housing and shelter around the globe. ATCO Frontec provides operational support services to government, defence and commercial clients. ATCO Energy Systems delivers essential energy for an evolving world through its electricity and natural gas transmission and distribution, and international operations. ATCO EnPower creates sustainable energy solutions in the areas of renewables, energy storage, industrial water and clean fuels. ATCO Australia develops, builds, owns and operates energy and infrastructure assets. ATCOenergy and Rümi provide retail electricity and natural gas services, home maintenance services and professional home advice that bring exceptional comfort, peace of mind and freedom to homeowners and customers. ATCO also has investments in ports and transportation logistics, the processing and marketing of fly ash, retail food services and commercial real estate. More information can be found at www.ATCO.com .

 

  Investor & Analyst Inquiries:  
Colin Jackson
Senior Vice President, Finance, Treasury & Sustainability
  Colin.Jackson@atco.com   
(403) 808 2636

 

  Media Inquiries:
  Kurt Kadatz  
Director, Corporate Communications
  Kurt.Kadatz@atco.com   
(587) 228 4571

 

SOURCE ATCO Ltd.

 

 

 

 Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/29/c6613.html  

 
 

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

PrairieSky Announces First Quarter 2024 Results, Record Oil Royalty Production

 

-

 

 PrairieSky Royalty Ltd. ("PrairieSky" or the "Company") (TSX: PSK) is pleased to announce its first quarter ("Q1 2024") operating and financial results for the three-month period ended March 31, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×